<topic rev="1.26" outputclass="drug" id="PHP4140">
	<title>GLIBENCLAMIDE</title>
	<prolog>
		<critdates>
			<revised modified="2019-12-16" golive="2021-04-01" />
		</critdates>
		<resourceid id="10.18578/BNF.111526249" appname="doi" />
	</prolog>
	<body>
		<p outputclass="interactionsLinks">
			List of individual interactants:
			<xref href="#bnf_int_1473" format="dita">glibenclamide</xref>
		</p>
		<data name="adultSpecificContent">true</data>
		<data name="vtmid">80870001</data>
		<data type="primary" name="classifications">
			<data name="classification">
				<data name="drugClassification">_663283150</data>
				<data name="classification">
					<data name="drugClassification">_606020038</data>
					<data name="inheritsFromClass">PHP34524</data>
				</data>
			</data>
		</data>
		<data name="primaryDomainOfEffect">
			<data name="domainOfEffect"> endocrine system </data>
		</data>
	</body>
	<topic rev="1.92" outputclass="indicationsAndDose" id="PHP67000">
		<title>Indications and dose</title>
		<body>
			<section outputclass="indicationAndDoseGroup">
				<sectiondiv outputclass="therapeuticIndications">
					<sectiondiv outputclass="therapeuticIndication">
						<p outputclass="indication">Type 2 diabetes mellitus</p>
					</sectiondiv>
				</sectiondiv>
				<p outputclass="routesOfAdministration">By mouth using tablets</p>
				<ul outputclass="patientGroups">
					<li outputclass="patientGroup adult">
						<p>Adult</p>
						<p>Initially 5 mg daily, adjusted according to response, dose to
							be taken with or immediately after breakfast; maximum 15 mg per
							day.</p>
					</li>
					<li outputclass="patientGroup adult">
						<p>Elderly</p>
						<p>2.5 mg daily, adjusted according to response, dose to be taken
							with or immediately after breakfast; maximum 15 mg per day.</p>
					</li>
				</ul>
			</section>
		</body>
	</topic>
	<topic rev="1.23" outputclass="unlicensedUse" id="PHP66795">
		<title>Unlicensed use</title>
		<body>
			<section>
				<sectiondiv>
					<p>Not licensed for use in breast feeding women with pre-existing
						diabetes.</p>
					<p>Not licensed for use in gestational diabetes.</p>
				</sectiondiv>
			</section>
		</body>
	</topic>
	<topic rev="1.36" outputclass="contraindications" id="PHP67114">
		<title>Contra-indications</title>
		<body>
			<section outputclass="contraindications">
				<p>
					<ph outputclass="contraindication">
						Avoid where possible in
						<xref type="bookmark" href="#PHP92524" format="dita">Acute
							porphyrias</xref>
					</ph>
				</p>
			</section>
		</body>
	</topic>
	<topic rev="2.1047" outputclass="sideEffects"
		id="PHP4140_sideeffects">
		<title>Side-effects</title>
		<body>
			<section outputclass="generalSideEffects">
				<sectiondiv outputclass="frequencies">
					<sectiondiv outputclass="notKnown">
						<p outputclass="title">Frequency not known</p>
						<p outputclass="sideEffects">
							<ph outputclass="sideEffect">Appetite abnormal</ph>
							;
							<ph outputclass="sideEffect">bone marrow disorders</ph>
							;
							<ph outputclass="sideEffect">epigastric discomfort</ph>
							;
							<ph outputclass="sideEffect">erythema nodosum</ph>
							;
							<ph outputclass="sideEffect">fever</ph>
							;
							<ph outputclass="sideEffect">gastrointestinal disorder</ph>
							;
							<ph outputclass="sideEffect">hypereosinophilia</ph>
							;
							<ph outputclass="sideEffect">SIADH</ph>
							;
							<ph outputclass="sideEffect">Stevens-Johnson syndrome</ph>
							;
							<ph outputclass="sideEffect">taste metallic</ph>
							;
							<ph outputclass="sideEffect">vision disorders</ph>
							;
							<ph outputclass="sideEffect">weight increased</ph>
						</p>
					</sectiondiv>
				</sectiondiv>
			</section>
		</body>
	</topic>
	<topic outputclass="pregnancy" id="PHP66910">
		<title>Pregnancy</title>
		<body>
			<section outputclass="generalInformation">
				<sectiondiv>
					<p>The use of sulfonylureas in pregnancy should generally be
						avoided because of the risk of neonatal hypoglycaemia; however,
						glibenclamide can be used during the second and third trimesters
						of pregnancy in women with gestational diabetes.</p>
				</sectiondiv>
			</section>
		</body>
	</topic>
	<topic outputclass="breastFeeding" id="PHP67181">
		<title>Breast feeding</title>
		<body>
			<section outputclass="generalInformation">
				<sectiondiv>
					<p>Glibenclamide can be used during breast-feeding in women with
						pre-existing diabetes.</p>
				</sectiondiv>
			</section>
		</body>
	</topic>
	<topic outputclass="medicinalForms" id="PHP4140-medicinalForms">
		<title>Medicinal forms</title>
		<body>
			<section outputclass="licensingVariationStatement">
				<p>There can be variation in the licensing of different medicines
					containing the same drug.</p>
			</section>
			<p>Forms available from special-order manufacturers include: oral
				suspension</p>
		</body>
	</topic>
</topic>